1. Oellerich M, Dasgupta A. Personalized Immunosuppression in Transplantation: Role of Biomarker Monitoring and Therapeutic Drug Monitoring. Waltham: Elsevier; 2016. pp. 1-51. 
2. Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can’t live without ... J Immunol. 2013;191(12):5785-91. 
3. Povzetek glavnih značilnosti zdravila Sandimmun Neoral. [cited 2018 Jan 10]. Available from: http://www.cbz.si/ZZZS/pao/bazazdr2.nsf/o/15F9EEB8ACC17C2AC12579C2003F5926/$File/s-015812.pdf 
4. Podatkovna baza Micromedex: Cyclosporine. [cited 2018 Jan 10]. Available from: https://www.micromedexsolutions.com/home/dispatch 
5. Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics. 2013;23(10):563-85. 
6. Finch A, Pillans P. P-glycoprotein and its role in drug-drug interactions. Aust Prescr. 2014;37(4):137-9. 
7. Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, et al. CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. Transplantation. 2013;95(6):821-7. 
8. Zhu HJ, Yuan SH, Fang Y, Sun XZ, Kong H, Ge WH. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Pharmacogenomics J. 2011;11(3):237-46. 
9. Maezono S, Sugimoto K, Sakamoto K, Ohmori M, Hishikawa S, Mizuta K, et al. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatr Transplant. 2005;9(3):315-23. 
10. Podatkovna baza UpToDate: Cyclosporine. [cited 2018 Jan 10]. Available from: https://www.uptodate.com/contents/search 
11. Kiani J, Imam SZ. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J. 2007;6(1):33. 
12. Colombo D, Lunardon L, Bellia G. Cyclosporine and herbal supplement interactions. J Toxicol. 2014;2014:145325. 
13. West SG. Rheumatology Secrets. Philadelphia: Elsevier; 2015. pp. 627-32. 
14. Russo E, Scicchitano F, Whalley BJ, Mazzitello C, Ciriaco M, Esposito S, et al. Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. Phytother Res. 2014;28(5):643-55. 
15. Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 2003;42(13):1071-88. 
16. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact. 2004;20(4):195-217. 
17. Tsunoda SM, Harris RZ, Christians U, Velez RL, Freeman RB, Benet LZ, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther. 2001;70(5):462-7. 
18. Vari CE, Tero-Vescan A, Imre S, Muntean DL. Therapeutic Drug Monitoring of Cyclosporine in Transplanted Patients. Possibilities, Controversy, Causes for Failure. Farmacia. 2012;60:595-601. 
19. Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36(2):396S-403S. 
20. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36(2):420S-5S. 
21. Büchler M, Johnston A. Seeking optimal prescription of cyclosporine ME. Ther Drug Monit. 2005;27(1):3-6. 
22. Einecke G, Mai I, Diekmann F, Fritsche L, Boehler T, Neumayer HH, et al. Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C( 0)) and C( 2) concentrations in stable renal allograft recipients. Transplant Proc. 2001;33(7-8):3102-3. 
23. Durlik M, Rauch C, Thyroff-Friesinger U, Streu H, Paczek L. Comparison of peak and trough level monitoring of cyclosporine treatment using two modern cyclosporine preparations. Transplant Proc. 2003;35(4):1304-7. 
24. Maziers N, Bulpa P, Jamart J, Delaunois L, Eucher P, Evrard P. Correlations between cyclosporine concentrations at 2 hours post-dose and trough levels with functional outcomes in de novo lung transplant recipients. Transplant Proc. 2012;44(9):2880-4. 
25. Saint-Marcoux F, Rousseau A, Le Meur Y, Estenne M, Knoop C, Debord J, et al. Influence of sampling-time error on cyclosporine measurements nominally at 2 hours after administration. Clin Chem. 2003;49(5):813-5. 
26. Wacke R, Drewelow B, Kundt G, Hehl EM, Bast R, Seiter H. Cyclosporine A: peak or trough level monitoring in renal transplant recipients? Transplant Proc. 2001;33(7-8):3122-3. 
27. Clinical Laboratory Medicine: Cyclosporin A. [cited 2018 Jan 10]. Available from: http://pathlabs.rlbuht.nhs.uk/overfrm.htm 
28. Tesfaye H, Prusa R, Jedlickova B, Segethova J. Cyclosporine use in miscellaneous clinical settings other than organ transplantations: is there any evidence for target levels? Ann Transplant. 2008;13(4):34-40. 
29. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al.; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562-75. 
30. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2(2):374-84. 
31. Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep. 2006;8(3):167-73. 
32. Ogawa H, Kameda H, Amano K, Takeuchi T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;19(2):162-9. 
33. Tsokos GC. Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. San Diego: Elsevier; 2016. pp. 533-9. 
34. Chi W, Yang P, Zhu X, Wang Y, Chen L, Huang X, et al. Production of interleukin-17 in Behcet’s disease is inhibited by cyclosporin A. Mol Vis. 2010;16:880-6. 
35. Cyclosporine Clinic. Guidelines For Monitoring Physicians. [cited 2018 Jan 10]. Available from: http://mpap.vch.ca/wp-content/uploads/sites/16/2014/05/Cyclosporine-Physician-Guidelines.pdf 
36. Bergner R, Landmann T, Tuleweit A, Abdel Mutallib S, Geibel G, Uppenkamp M. Ist die Bestimmung von Cyclosporin Spiegeln in der Rheumatologie erforderlich? [cited 2018 Jan 10]. Available from: http://dgrh-kongress.de/fileadmin/media/Die_DGRH/Jahreskongresse/Abstracts_2008_PDFs/K08_RA2.08.pdf 
37. Waldman M, Austin HA. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1617-30. 
38. Merlin T. Membranous nephropathy: role of cyclosporin therapy. Nephrology (Carlton). 2006;11(S1):S166-9. 
39. Ghiggeri GM, Catarsi P, Scolari F, Caridi G, Bertelli R, Carrea A, et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther. 2004;26(9):1411-8. 
40. Gulati A, Bagga A, Gulati S, Mehta KP, Vijayakumar M; Indian Society of Pediatric Nephrology. Management of steroid resistant nephrotic syndrome. Indian Pediatr. 2009;46(1):35-47. 
41. Passweg JR, Marsh JC. Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hematology (Am Soc Hematol Educ Program). 2010;2010(1):36-42. 
42. Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123(5):634-41. 
43. Schmidt S, Pleyer U. Ciclosporin-Monitoring bei Patienten mit chronischer Uveitis. Ophthalmologe. 2005;102(4):349-54. 
44. Heydendael VM, Spuls PI, Ten Berge IJ, Opmeer BC, Bos JD, de Rie MA. Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. Br J Dermatol. 2002;147(1):122-9. 
45. Focal segmental glomerulosclerosis: use of cyclosporin A. The CARI Guidelines – Caring for Australasians with Renal Impairment. [cited 2019 Mar 15]. Available from: http://www.cari.org.au/Archived%20guidelines/CKD%20archived/prevention%20of%20progression/FSGS_use_of_cyclosporin_A.pdf 
46. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al.; North America Nephrotic Syndrome Study Group. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int. 1999;56(6):2220-6. 
47. Guidelines for the diagnosis and treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Nordic MDS Group. [cited 2019 Mar 15]. Available from: https://www.nmds.org/attachments/article/92/Guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20MDS%20and%20CMML_17.pdf 
48. Clarke W, Dasgupta A. Clinical Challenges in Therapeutic Drug Monitoring. Oxford: Elsevier; 2016. 
49. Morris RG. Cyclosporin therapeutic drug monitoring—an established service revisited. Clin Biochem Rev. 2003;24(2):33-46. 
50. Therapeutisches Drug Monitoring von Cyclosporin A und Tacrolimus – Ergebnisse der Vergleichsmessungen zwischen LCMS und den bisher eingesetzten Immunoassays. [cited 2018 Jan 10]. Available from: http://www.labor-lademannbogen.de/fileadmin/_migrated/content_uploads/TDM-neu_01.pdf 
51. Immunsuppressiva – Therapeutic Drug Monitoring (TDM) mittels LC-MS/MS: Bessere Patientenführung durch exakte Analysenwerte – Cyclosporin A – Tacrolimus – Sirolimus – Everolimus. [cited 2018 Jan 10]. Available from: http://www.labor-lademannbogen.de/fileadmin/_migrated/content_uploads/JUNI0407_01.pdf 
52. Andrews DJ, Cramb R. Cyclosporin: revisions in monitoring guidelines and review of current analytical methods. Ann Clin Biochem. 2002;39(Pt 5):424-35. 
53. DoseMe. [cited 2018 Jan 10]. Available from: https://doseme.com.au/ 
54. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, Bernard N, Thiry P, Le Meur Y, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet. 2006;45(9):905-22. 
